Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leblanc, R.
Right arrow Articles by Masson, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leblanc, R.
Right arrow Articles by Masson, H.
NEUROLOGY 1988;38:1887
© 1988 American Academy of Neurology

Neurobehavioral effects of intrathecal somatostatinergic treatment in subhuman primates

R. Leblanc, MSc, MD, FRCSC, S. Gauthier, MD, FRCPC, M. Gauvin, DVM, R. Quirion, PhD, R. Palmour, PhD and H. Masson, MD, FRCPC

Department of Neurology and Neurosurgery, the Centre for Studies in Aging, the Allan Memorial Institute, and the Douglas Hospital Research Centre, McGill University, Montreal, Quebec, Canada.

We infused somatostatin and its long-acting analogue (SMS 201-995) into the intracranial subarachnoid space of eight monkeys. Chronic infusions of SMS 201-995 produced marked neurotoxic effects characterized by truncal ataxia, dysmetria, and severe bradykinesia, with normal level of consciousness. Subcutaneous injection of apomorphine, a dopaminergic agonist, promptly reversed these effects. Further studies are required before intrathecal somatostatin replacement therapy can be offered to patients with Alzheimer's disease.

Address correspondence and reprint requests to Dr. Leblanc, Montreal Neurological Institute, 3801 University Street, Montreal, Quebec H3A 2B4, Canada.

Received February 15, 1988. Accepted for publication in final form June 6, 1988.




This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
L. F. Agnati, S. Ferre, C. Lluis, R. Franco, and K. Fuxe
Molecular Mechanisms and Therapeutical Implications of Intramembrane Receptor/Receptor Interactions among Heptahelical Receptors with Examples from the Striatopallidal GABA Neurons
Pharmacol. Rev., September 1, 2003; 55(3): 509 - 550.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
X Su, M B Burton, and G F Gebhart
Effects of octreotide on responses to colorectal distension in the rat
Gut, May 1, 2001; 48(5): 676 - 682.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
M. Rocheville, D. C. Lange, U. Kumar, S. C. Patel, R. C. Patel, and Y. C. Patel
Receptors for Dopamine and Somatostatin: Formation of Hetero-Oligomers with Enhanced Functional Activity
Science, April 7, 2000; 288(5463): 154 - 157.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by AAN Enterprises, Inc.